Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Beam Therapeutics Inc. of shares of its common stock for up to a maximum offering price of $300 million.
Based in Cambridge, Massachusetts, Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Yoojin Nairn-Kim and Tomer Magid. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Partner Po Sit provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.